Fresenius Medical Care AG (FMS)
20.24
-0.52
(-2.50%)
USD |
NYSE |
Apr 25, 14:48
Fresenius Medical Care Cash from Financing (Quarterly): -800.38M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -800.38M |
| September 30, 2023 | -447.78M |
| June 30, 2023 | -766.06M |
| March 31, 2023 | 2.163M |
| December 31, 2022 | -197.17M |
| September 30, 2022 | -448.74M |
| June 30, 2022 | -760.55M |
| March 31, 2022 | -299.20M |
| December 31, 2021 | -425.78M |
| September 30, 2021 | -330.31M |
| June 30, 2021 | -412.66M |
| March 31, 2021 | -43.28M |
| December 31, 2020 | -591.98M |
| September 30, 2020 | -906.03M |
| June 30, 2020 | -1.289B |
| March 31, 2020 | -255.51M |
| December 31, 2019 | -186.27M |
| September 30, 2019 | -586.18M |
| June 30, 2019 | -570.26M |
| March 31, 2019 | 820.32M |
| December 31, 2018 | 48.67M |
| September 30, 2018 | 84.02M |
| June 30, 2018 | -1.353B |
| March 31, 2018 | 415.03M |
| December 31, 2017 | -251.95M |
| Date | Value |
|---|---|
| September 30, 2017 | -386.48M |
| June 30, 2017 | -421.97M |
| March 31, 2017 | 155.94M |
| December 31, 2016 | -264.02M |
| September 30, 2016 | -265.12M |
| June 30, 2016 | -161.13M |
| March 31, 2016 | 115.07M |
| December 31, 2015 | -380.54M |
| September 30, 2015 | -238.48M |
| June 30, 2015 | -140.74M |
| March 31, 2015 | -247.23M |
| December 31, 2014 | 558.68M |
| September 30, 2014 | 73.00M |
| June 30, 2014 | 132.92M |
| March 31, 2014 | 115.76M |
| December 31, 2013 | -47.55M |
| September 30, 2013 | -203.41M |
| June 30, 2013 | -272.12M |
| March 31, 2013 | -254.08M |
| December 31, 2012 | -213.72M |
| September 30, 2012 | -435.97M |
| June 30, 2012 | -157.08M |
| March 31, 2012 | 1.262B |
| December 31, 2011 | 390.92M |
| September 30, 2011 | -276.59M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.289B
Minimum
Jun 2020
2.163M
Maximum
Mar 2023
-490.26M
Average
-447.78M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | -0.0533M |
| Biophytis SA | -- |
| TC BioPharm (Holdings) PLC | -- |
| DaVita Inc | -403.25M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 766.67M |
| Cash from Investing (Quarterly) | -101.71M |
| Free Cash Flow | 2.105B |
| Free Cash Flow Per Share (Quarterly) | 0.8493 |
| Free Cash Flow to Equity (Quarterly) | 780.68M |
| Free Cash Flow to Firm (Quarterly) | 566.54M |
| Free Cash Flow Yield | 17.72% |